Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37436| Title: | Post‑alemtuzumab Graves’ disease remitting after switch to ocrelizumab | Authors: | POPESCU, Veronica Beirinckx, Annemie Decallonne, Brigitte |
Issue Date: | 2022 | Publisher: | SPRINGER HEIDELBERG | Source: | Acta neurologica belgica, 122 (4), p. 1117-1120 | Notes: | Popescu, V (corresponding author), Univ MS Centrum Pelt Hasselt, Noorderhart Hosp, Pelt, Belgium.; Popescu, V (corresponding author), Hasselt Univ, Hasselt, Belgium. veronica.popescu@noorderhart.be |
Keywords: | Multiple sclerosis;Alemtuzumab;Graves’ disease;Ocrelizumab;Autoimmunity;Therapeutics | Document URI: | http://hdl.handle.net/1942/37436 | ISSN: | 0300-9009 | e-ISSN: | 2240-2993 | DOI: | 10.1007/s13760-022-01962-9 | ISI #: | 000798323700002 | Rights: | The Author(s) under exclusive licence to Belgian Neurological Society 2022 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2024 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Post-alemtuzumab Graves’ disease remitting after switch to ocrelizumab.pdf Restricted Access | Published version | 564.2 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.